MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update

Provided By PR Newswire

Last update: May 14, 2025

Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability